16.01.2017 09:15

A successful year for Swiss blockchain startup Decent

DECENT is an Open-Source decentralized content distribution platform that utilizes Blockchain to ensure trust and security for content creators and enterprises. After the raising over $4.2 million worth of Bitcoins from their Initial Coin Offering, the startup expanded to China and closed additional partnerships.

16.01.2017 08:48

Xigen’s Brimapitide Delivers Positive Phase II Results in Inflammatory Eye Disease

Xigen, a SwissCompany developing therapeutic peptides for the treatment of inflammatory diseases, announced the online publication of successful Phase II results for its lead compound Brimapitide (XG-102) in the American Journal of Ophthalmology.


13.01.2017 12:40

Anokion Announces Exclusive Strategic Collaboration with Celgene

Under the terms of the collaboration agreement, Anokion received a $45 million upfront payment and is eligible to receive a future payment of an additional $10 million based on certain preclinical development achievements. As part of the strategic collaboration agreement, Celgene obtained an equity interest in Anokion and the exclusive right to acquire Anokion at pre-specified option exercise points.


12.01.2017 09:07

Squirro selected for the SuperCharger Fintech Accelerator

SuperCharger is an accelerator program for global fintech companies planning to expand to the Asian market. The program is backed by companies such as Standard Chartered and Fidelity International.

12.01.2017 08:16

L’interactivité sera au cœur du Salon STIL 2017

La 4ème édition du Salon des Technologies et de l’Innovation de Lausanne se tiendra le 2 mars prochain au SwissTech Convention Center de l’EPFL. Comme nous l’a expliqué la Présidente du STIL 2017, Victoria Letertre, le salon s’est fixé cette année un but ambitieux: faire découvrir les technologies des différentes entreprises et laboratoires présents de manière interactive pour les visiteurs.



11.01.2017 16:53

PIQUR announces partnership with second largest private French pharmaceutical group

PIQUR Therapeutics AG, a Swiss clinical-stage pharmaceutical company, and Pierre Fabre, announced today that they have signed a collaboration agreement for the development of PIQUR’s lead compound PQR309 in dermato-oncology.

11.01.2017 07:24

Sophia Genetics Hereditary Cancer Solution Lands CE-IVD Mark

Early genomic testing can help identify an increased risk of particular types of cancer due to gene variants passed on from parent to child. Sophia Genetics Hereditary Cancer Solution helps quickly screen the 27 most relevant genes associated with hereditary cancer. It is the first solution of its kind which is CE-IVD marked.

Show All


24th - 25th Jan 2017 08:00-18:00

WorldWebForum 2017 Stage one, Elias-Canetti-Strasse 146, 8050 Zurich

Show All


25.01.2017 17:00

Technologie- und Innovationsförderung: Welche Finanzierungsquellen gibt es? Auditorium Hochschule Luzern - Wirtschaft, Luzern

Top viewed

Show All





Competing with the best